Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL350448 | 1.00 | SCD5 (0.39) | SCD5NPY5RHSD11B1TACR1CYP11B2 | |
| SCHEMBL348247 | 0.86 | HSD11B1 (0.43) | SCD5NPY5RHSD11B1CYP11B2USP30 | |
| SCHEMBL348248 | 0.86 | HSD11B1 (0.43) | SCD5NPY5RHSD11B1CYP11B2USP30 | |
| SCHEMBL349363 | 0.86 | HSD11B1 (0.43) | NPY5RHSD11B1 | |
| SCHEMBL349364 | 0.86 | HSD11B1 (0.43) | NPY5RHSD11B1 | |
| SCHEMBL17584778 | 0.80 | AVPR1A (0.41) | SCD5NPY5RHSD11B1 | |
| SCHEMBL350104 | 0.79 | HSD11B1 (0.56) | NPY5RHSD11B1 | |
| SCHEMBL3970346 | 0.78 | HSD11B1 (0.54) | NPY5RHSD11B1 | |
| SCHEMBL349129 | 0.78 | HSD11B1 (0.55) | NPY5RHSD11B1USP30 | |
| SCHEMBL17586449 | 0.78 | USP30 (0.42) | SCD5HSD11B1CYP11B2USP30RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957229-B2 | Amido compounds and their use as pharmaceuticals | INCYTE HOLDINGS CORPORATION (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170334847-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION | 2017-11-23 | — | — | US | disclosed |
| EP-2963021-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Holdings Corporation (US) | 2016-01-06 | — | — | EP | disclosed |
| US-9126927-B2 | Amido compounds and their use as pharmaceuticals | INCYTE HOLDINGS CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| EP-1756063-B1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20120015928-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION (US) | 2012-01-19 | — | — | US | disclosed |
| US-8058288-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2011-11-15 | — | — | US | disclosed |
| US-20100256114-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-7776874-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1756063-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080255154-A1 | Cycloalkylcarbonyl-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-ones: N-methyl-5-[4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'-yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide; 11- beta hydroxyl steroid dehydrogenase type 1 inhibitors; mineralcorticoid receptor antagonists; diabetes | INCYTE CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-02 | — | — | US | disclosed |
| EP-1756063-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005110992-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334847-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | SCD5 861/4885NPY5R 642/4885HSD11B1 1/4885 |
| US-20100256114-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | SCD5 861/4885NPY5R 642/4885HSD11B1 1/4885 |
| US-20120015928-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | SCD5 861/4885NPY5R 642/4885HSD11B1 1/4885 |
| US-20080255154-A1 | Cycloalkylcarbonyl-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-ones: N-methyl-5-[4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'-yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide; 11- beta hydroxyl steroid dehydrogenase type 1 inhibitors; mineralcorticoid receptor antagonists; diabetes | HSD11B1, NR3C2, SRD5A1 | SCD5 1032/4885NPY5R 553/4885HSD11B1 1/4885 |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | SCD5 861/4885NPY5R 642/4885HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.